Nicotine Patches, Nicotine Lozenges, Individualized Quitting Messages, and Motivational Interviewing at Lung Cancer Screening Sites in Helping Current Smokers Reduce or Quit Smoking, CASTL study
This randomized phase IV trial studies how well nicotine patches, nicotine lozenges, individualized quitting messages, and motivational interviewing at lung cancer screening sites work in helping current smokers reduce or quit smoking. Nicotine patches, nicotine lozenges, individualized quitting messages, or motivational interviewing may help doctors determine the best type of treatment, or combination of treatments, to offer patients who are current smokers in order to help reduce the number of cigarettes smoked or quit smoking. It may also increase the benefits of lung cancer screening by providing a blue print of best practices for screening sites to deliver tobacco treatment to their patients who are smokers, in a way that does not add burden to screening site staff and increases the chances of patients quitting smoking.
- SITE ELIGIBILITY (AS PER SC SELF-REPORT)
- Must be designated as an American College of Radiology (ACR) designated lung cancer screening site
- Reports at least one year of lung cancer screening experience
- Reports conducting at least 20 new initial screenings per month
- SITE COORDINATOR (SC) ELIGIBILITY (AS PER SELF-REPORT)
- Employed at participating lung cancer screening site
- PATIENT ELIGIBILITY (AS PER SELF-REPORT)
- Has a scheduled baseline or annual follow-up low dose computed tomography (LDCT) lung cancer screening within 60 business days OR has had a baseline or annual follow-up LDCT lung cancer screening within the last 60 business days and received the result for that scan OR has had a baseline or annual follow-up LDCT lung cancer screening but has not received the result for that scan
- Have at least a 20 pack-year history of smoking (per site report)
- Currently a smoker, defined as self-reported cigarette smoking (some days, every day) within the past 30 days
- Must be reachable by telephone
- Must be English or Spanish speaking due to the study materials being available only these languages and limited available resources for translation
- PACT ANCILLARY STUDY PATIENT ELIGIBILITY: Listed as eligible for CASTL by the site as per the site weekly log
- PACT ANCILLARY STUDY PATIENT ELIGIBILITY: Self-Identifies as African-American on the site weekly log
- PACT ANCILLARY STUDY PATIENT ELIGIBILITY: Refused participation to CASTL either actively (communicated they are not interested) or passively (did not respond to an invitation to CASTL)
- PACT ANCILLARY STUDY PATIENT ELIGIBILITY: Must be reachable by telephone
- PACT ANCILLARY STUDY PATIENT ELIGIBILITY: Must be English speaking due to the study materials being available in English only and limited available resources for translation
- PATIENT (AS PER SELF-REPORT)
- NRT is medically contraindicated (e.g., recent heart attack within the last 2 weeks or, unstable/worsening angina)
- Smokers who are receiving other tobacco treatment services or have used cessation medications (NRT, bupropion, varenicline) within the past month with the intent to quit smoking (used NRT 15+ days in the past month).
- Patients with complications that may prevent them from participating in the study (per the discretion of the screening site coordinator or study principal investigator [PI]).
Rush University Medical Center